ASH 2023 | SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCL
In this video, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses results from the Phase III SYMPATICO trial (NCT03112174), which is comparing the safety and efficacy of ibrutinib + venetoclax versus ibrutinib + placebo in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This all-oral combination demonstrated a statistically significant improvement in progression-free survival (PFS) compared to the placebo arm, with similar adverse events (AEs) observed in both arms. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio
